Holen Sie sich die Stockscreener-App
3.45
3.09%
-0.11
Schlusskurs vom Vortag:
$3.56
Offen:
$3.6
24-Stunden-Volumen:
1.75M
Relative Volume:
1.20
Marktkapitalisierung:
$1.18B
Einnahmen:
$787.89M
Nettoeinkommen (Verlust:
$20.56M
KGV:
58.97
EPS:
0.0585
Netto-Cashflow:
$96.54M
1W Leistung:
-7.51%
1M Leistung:
+14.24%
6M Leistung:
+39.68%
1J Leistung:
-23.16%
1-Tages-Spanne:
$3.44
$3.60
1-Wochen-Bereich:
$3.44
$3.79
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.45 | 1.21B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
247.90 | 40.70B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
72.69 | 12.03B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
58.87 | 11.78B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
105.41 | 8.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
65.12 | 8.32B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx (GDRX) Q2 2026 Earnings Call Transcript - AOL.com
GDRX Maintains Underweight Rating -- Price Target Raised to $4.0 - GuruFocus
Q2 2026 GoodRx Holdings, Inc. Earnings Call Transcript - GuruFocus
Justin Fengler Net Worth (2026) - GuruFocus
Big GoodRx (NASDAQ: GDRX) backer prepares share sale - Stock Titan
Technology Crossover Management X Ltd. Buys Shares of 1,653,566 GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) Results at a Glance: The Available Figures Are Largely Near Expectations at the Close; Stock Move - vinanet.vn
GoodRx Holdings Inc (GDRX) (Q2 2026) Earnings Call Highlights: R - GuruFocus
GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen - MarketBeat
Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX) - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
GDRX Maintained by UBS -- Price Target Raised to $3.75 - GuruFocus
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook - Yahoo Finance
GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise - Yahoo Finance
UBS Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $3.75 - Moomoo
GoodRx (NASDAQ:GDRX) Trading Down 5.1%What's Next? - MarketBeat
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope (NASDAQ:GDRX) - Seeking Alpha
GDRX Maintained by Citigroup -- Price Target Raised to $5.00 - GuruFocus
GoodRx (NASDAQ:GDRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
GDRX Maintained by TD Cowen -- Price Target Raised to $5.00 - GuruFocus
GDRX Q2 Deep Dive: Pharma Direct and Subscription Growth Drive Upgraded Outlook - finance.yahoo.com
GOODRX HOLDINGS, INC. : CITIGROUP RAISES TARGET PRICE TO $5 FROM $4 - Bitget
GDRX Maintains Overweight by Wells Fargo -- Price Target Raised to $5.00 - GuruFocus
GoodRx Holdings Price Target Raised to $5.00/Share From $3.50 by Wells Fargo - Moomoo
Prescription savings giant GoodRx could be opening office at The Pearl - The Business Journals
GoodRx Holdings Inc (GDRX) Stock Analysis & Forecast - TradingKey
GoodRx Holdings Inc (GDRX) Stock News Today - TradingKey
Wells Fargo & Company Boosts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - MarketBeat
GoodRx Holdings Inc (GDRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.7 - TradingView
Morgan Stanley Adjusts Price Target on GoodRx to $4 From $3, Maintains Equalweight Rating - marketscreener.com
Earnings call transcript: GoodRx lifts 2026 outlook after Q2 revenue beat - Investing.com Canada
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.55, Implies 9% Upside - TradingView
Transcript : GoodRx Holdings, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
GoodRx Lets Customers Shop Where They Want, CEO Says - marketscreener.com
GoodRx Q2 Earnings Call Highlights - MarketBeat
GoodRx (NASDAQ:GDRX) Stock Price Up 15.7%Here's Why - MarketBeat
GDRX: Pharma Direct and subscriptions drove Q2 outperformance, leading to raised 2026 guidance - TradingView
GoodRx Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
GDRX Looks 42.2% Undervalued on GF Value™ - GuruFocus
GDRX SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
GoodRx (NASDAQ:GDRX) Posts Earnings Results, Hits Estimates - MarketBeat
GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates - Yahoo Finance
GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Tranche Update on GoodRx Holdings, Inc.'s Equity Buyback Plan announced on February 29, 2024. - marketscreener.com
Is GoodRx Holdings Inc (GDRX) Undervalued After Q2 Earnings? EPS - GuruFocus
GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars - Barchart.com
GoodRx Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aug 05 (Reuters)GoodRx Holdings Q2 Revenue - Moomoo
GDRX: Pharma Direct and subscription growth drove raised 2026 guidance despite lower transactions - TradingView
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q2 EPS; Offers Guidance - StreetInsider
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
6.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):